Revelation Biosciences, Inc. (NASDAQ:REVB – Free Report) shares are set to reverse split before the market opens on Tuesday, October 20th. The 1-7 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the closing bell on Monday, October 19th.
Revelation Biosciences Stock Performance
Shares of NASDAQ REVB traded down $0.28 during midday trading on Friday, reaching $0.48. The stock had a trading volume of 632,488 shares, compared to its average volume of 40,664. The company’s 50 day moving average price is $0.94 and its 200 day moving average price is $1.03. Revelation Biosciences has a twelve month low of $0.47 and a twelve month high of $5.80. The firm has a market cap of $1.93 million, a price-to-earnings ratio of -0.04 and a beta of -0.07.
Revelation Biosciences (NASDAQ:REVB – Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.87) EPS for the quarter, beating analysts’ consensus estimates of ($0.88) by $0.01. Equities analysts forecast that Revelation Biosciences will post -5.18 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
Separately, Weiss Ratings lowered Revelation Biosciences from a “sell (e+)” rating to a “sell (e)” rating in a research report on Wednesday. One analyst has rated the stock with a Sell rating. According to data from MarketBeat.com, the company presently has an average rating of “Sell”.
Read Our Latest Analysis on REVB
Revelation Biosciences Company Profile
Revelation Biosciences, Inc is a clinical-stage biotechnology company focused on developing therapies that activate and regulate the body’s innate immune system. Its research is aimed primarily at addressing infectious diseases and inflammatory conditions, particularly those affecting the respiratory system.
The company’s pipeline includes intranasal product candidates designed to stimulate localized immune responses in the nose and airways. Its lead candidate, REVTx-99, has been developed as an investigational therapy for respiratory conditions, including the prevention or reduction of complications associated with severe respiratory infections.
See Also
- Five stocks we like better than Revelation Biosciences
- Bank of America Stock Sell-Off Looks Like a Buying Opportunity
- AST SpaceMobile Is Down 67%—Could SpaceX’s Mobile Push Deepen the Selloff?
- GlobalFoundries’ $21 Billion Deal Could Change the Economics of Chipmaking
- Fundamental and Technicals Signals Align for Costco: Is the Stock Finally Breaking Out?
Receive News & Ratings for Revelation Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revelation Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
